(TheNewswire)
Toronto, Ontario – TheNewswire – February 9, 2021 - Ventripoint Diagnostics Ltd. (" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) has released the company’s new Investor Relations (IR) section on the company’s website.
The new IR section of the website provides, quarterly and annual financial statements and MD&A filings, the latest investor presentation, links to videos of the presentations, new releases, contact information to our investor relations firms, past and upcoming events, ability to enroll in the distribution list for alerts, a link to current stock market information including share price and bid and ask quotes, and in-depth analysis of strategic initiatives.
Ventripoint aims to enhance the communication between the company and its shareholders and potential investors.
The Investor Relations webpage can be accessed here: https://www.ventripoint.com/investor-relations
About Ventripoint Diagnostics Ltd.
Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.
For further information, please contact:
Mr. Jonathan Robinson
Email : JRobinson@oakhillfinancial.ca
Phone: (416) 669-1001
Or
Mr. Clay Chase
Email: cc@sdthc.com
Phone: 858-456-7300